Science, Awareness, and Hope for Patients Living with Arthritis
World Arthritis Day is an opportunity to recognize the millions of people living with arthritis and the daily challenges it can bring, including persistent pain, stiffness, fatigue, and reduced mobility. Arthritis is not a single disease but a group of more than 100 conditions, including osteoarthritis, rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. While modern treatments have transformed arthritis care, many patients continue to experience persistent symptoms or progressive disease. [1]
For decades, treatment has focused primarily on controlling inflammation, relieving pain, and slowing disease progression. Today, advances in regenerative medicine are opening new areas of research. Mesenchymal stem/stromal cells (MSCs) are being studied for their potential to regulate immune responses, reduce inflammation, and support tissue repair, offering a different approach from conventional symptom management. [2,4]
At the same time, genomics is helping move arthritis care toward greater personalization. Understanding individual genetic and biological differences may help researchers identify why patients respond differently to treatment and guide the development of more targeted regenerative approaches. [6,12] Together, regenerative medicine and genomics offer promising new possibilities for the future of arthritis care, while emphasizing the importance of rigorous research, patient safety, and responsible clinical development.
From Symptom Control to Regenerative Medicine
Modern arthritis treatments have transformed patient care. Anti-inflammatory medicines, corticosteroids, disease-modifying antirheumatic drugs (DMARDs), and biologic therapies can significantly reduce inflammation and help slow disease progression.
However, not every patient achieves adequate or lasting control. This has encouraged researchers to explore approaches that go beyond symptom management, approaches that may help restore immune balance and support tissue repair.
Regenerative medicine is one of the most actively studied areas of this research.
The Potential of Mesenchymal Stem/Stromal Cells
Mesenchymal stem/stromal cells (MSCs) are among the most extensively studied cell types in regenerative medicine. They can be derived from sources such as bone marrow, adipose tissue, and umbilical cord. [2]
MSCs interact with their surrounding environment and release biological signals that may help regulate excessive immune activity, reduce inflammatory responses, and support tissue repair. [2] Their potential is being investigated differently depending on the type of arthritis.
In rheumatoid arthritis, researchers are studying whether MSCs can help rebalance abnormal immune responses and reduce disease activity. [4,5]
In osteoarthritis, where joint degeneration plays a central role, research focuses on reducing pain, improving function, and supporting the biological environment of damaged joint tissues. [7–10]
MSCs may also release extracellular vesicles and exosomes, which carry proteins, lipids, and microRNAs that can influence the behavior of other cells. This has opened another important area of regenerative medicine research. [3]
What Does the Clinical Evidence Show?
Clinical research into MSC therapy has expanded considerably. A 2025 systematic review and meta-analysis of 42 randomized controlled trials involving more than 2,000 participants reported encouraging findings across several autoimmune and rheumatic conditions, including improvements in disease activity and inflammatory markers, while also highlighting the need for further research. [4]
In rheumatoid arthritis, clinical studies have reported reductions in disease activity and inflammatory markers following MSC-based treatment. Researchers are also investigating why some patients respond better than others and whether repeated treatment may be beneficial. [5]
For osteoarthritis, the evidence is more variable. A 2024 systematic review and meta-analysis found that the evidence for MSCs in chronic knee OA pain remained uncertain, highlighting variability between studies and treatment approaches. [7] More recent trials and analyses have reported encouraging improvements in pain and function, although further research is needed to establish consistent long-term benefits. [8–10]
These findings are encouraging, but MSC-based therapy remains an emerging field of clinical research. The optimal cell source, dose, treatment frequency, delivery method, patient selection, and long-term effectiveness are still being investigated. [4,7,9]
The Genomic Dimension: Why DNA GTx Matters
One of the key challenges in arthritis care is that patients can respond differently to the same treatment. Genomics may help address this variability by providing insights into an individual’s genetic background, immune-related pathways, and the biological mechanisms underlying disease.
Research has identified genetic and molecular factors associated with rheumatoid arthritis and osteoarthritis that may contribute to disease susceptibility and help researchers better understand differences between patients. [6,12]
At our partner DNA GTx, genome-guided approaches are being explored to better understand individual biological profiles and disease mechanisms. This work supports the broader goal of developing more personalized regenerative medicine strategies, in which treatment approaches may be informed by an individual’s biological characteristics.
By combining genomic insights with Stemwell’s expertise in cell therapy, there is potential to advance more targeted and individualized approaches to regenerative medicine.
Innovation With Responsibility
With innovation comes responsibility. Although stem cell and regenerative therapies offer exciting possibilities, many applications remain under clinical investigation. Researchers continue to study their long-term safety, effectiveness, and the best ways to deliver these therapies. [4,7,9]
Patients should therefore seek treatment through regulated clinical trials or appropriately approved medical programs and be cautious of unlicensed clinics that promise guaranteed results.
At Stemwell, rigorous quality and safety standards are an essential part of advancing regenerative medicine. Continued research, appropriate patient selection, clinical monitoring, and long-term follow-up remain critical to establishing the true potential of these therapies.
Looking Toward the Future
The next generation of arthritis care may bring together cell therapy, genomics, biologics, and other regenerative technologies.
The goal is to move beyond simply managing symptoms toward a deeper understanding of the biological mechanisms driving disease, while developing increasingly precise approaches to support immune regulation, tissue health, and patient outcomes.
On World Arthritis Day, we recognize both the progress already achieved and the work still ahead. For people living with arthritis, advances in regenerative medicine and genomics offer new possibilities, new questions, and new hope.
At Stemwell and DNA GTx, we remain committed to responsible research, scientific innovation, and the development of more personalized approaches to regenerative medicine.
Regenerative and genomic therapies discussed in this article are areas of ongoing research. Their availability, indications, and clinical effectiveness may vary. Patients should consult qualified healthcare professionals before considering any treatment.
Speak to Stemwell today to find out more
Stem cell therapy represents an exciting new treatment avenue for hamstring injuries, with the potential to promote quicker healing and improve your overall quality of life. Our expert team at Stemwell are dedicated to supporting you and finding the right treatment option to meet your needs.
If you would like to find out more about stem cell therapy you can contact us with any questions, or apply today to check your eligibility.
References
[1] GBD 2021 Rheumatoid Arthritis Collaborators. Global, regional, and national burden of rheumatoid arthritis, 1990–2020, and projections to 2050. Lancet Rheumatol. 2023;5(10):e594-e610.
[2] Yang G, Fan X, Liu Y, et al. Immunomodulatory Mechanisms and Therapeutic Potential of Mesenchymal Stem Cells. Stem Cell Rev Rep. 2023 Apr 14;19(5):1214–1231. doi: 10.1007/s12015-023-10539-9
[3] Mesenchymal Stem Cell Therapy in Osteoarthritis and Rheumatoid Arthritis: A Systematic Review of Exosomal microRNAs. Biologics. 2025;19:571417. doi: 10.2147/BTT.S571417
[4] Zeng L, Zhang Y, Li Y, et al. Efficacy and safety of mesenchymal stromal cell transplantation in the treatment of autoimmune and rheumatic immune diseases: a systematic review and meta-analysis of randomized controlled trials. Stem Cell Research & Therapy. 2025;16(1):65. doi: 10.1186/s13287-025-04184-x
[5] Mesa LE, Zhang Y, Li Y, et al. Safety and efficacy of mesenchymal stem cells therapy in rheumatoid arthritis: a systematic review and meta-analysis of clinical trials. PLoS One. 2023 Jul 27;18(7):e0284828. doi: 10.1371/journal.pone.0284828
[6] Song X, Lv S, Du L, et al. Genome-Wide Association Analysis and Multi-Omic Mendelian Randomization Insight Into the Molecular Network of Immune-Related Dysfunction in the Pathogenesis of Rheumatoid Arthritis. Int J Rheum Dis. 2025 Nov;28(11):e70479. doi: 10.1111/1756-185x.70479
[7] Sadeghirad B, et al. Mesenchymal stem cells for chronic knee pain secondary to osteoarthritis: A systematic review and meta-analysis of randomized trials. Osteoarthritis Cartilage. 2024 Oct;32(10):1207-1219. doi: 10.1016/j.joca.2024.04.021
[8] Chen C, Wu S, Ma X, et al. Multiple intra-articular injections of umbilical cord mesenchymal stem cells in treating severe knee osteoarthritis: a triple-blind randomized controlled trial. Stem Cell Res Ther. 2026;17:524. doi: 10.1186/s13287-026-05224-w
[9] Lohrasbi E, Babaie S, Hamedfar H, et al. Regenerative Therapy in Osteoarthritis Using Umbilical Cord-Origin Mesenchymal Stem Cells: A Critical Appraisal of Clinical Safety and Efficacy Through Systematic Review and Meta-Analysis. Stem Cells Int. 2025;2025:4261166. doi: 10.1155/sci/4261166
[10] Clinical Efficacy and Safety of the Intra-articular Injection of Autologous Adipose-Derived Mesenchymal Stem Cells for Knee Osteoarthritis – A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial. Osteoarthritis Cartilage. 2025.
[11] Dudek D, Walczuk E, Wajda A, Paradowska-Gorycka A. Mesenchymal stem cells in systemic sclerosis therapy. Reumatologia. 2020 Oct 18;58(5):324–330. doi: 10.5114/reum.2020.99995
[12] Zhang N, et al. Cross-Tissue Transcriptome-Wide Association Study Prioritizes Candidate Genes and Compound-Associated Signatures for Osteoarthritis. Curr Pharm Des. 2026. doi: 10.2174/0113816128481898260605051256
